Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Oncocyte Corp (OCX)
Oncocyte Corp (OCX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,319
  • Shares Outstanding, K 8,261
  • Annual Sales, $ 960 K
  • Annual Income, $ -72,900 K
  • 60-Month Beta 0.78
  • Price/Sales 14.81
  • Price/Cash Flow 3.41
  • Price/Book 0.67
Trade OCX with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 59.09%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.57
  • Number of Estimates 1
  • High Estimate -1.57
  • Low Estimate -1.57
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.77 +10.65%
on 02/02/24
3.44 -10.90%
on 01/25/24
-0.25 (-7.68%)
since 01/23/24
3-Month
2.32 +32.11%
on 12/29/23
4.30 -28.80%
on 11/27/23
-0.90 (-22.80%)
since 11/22/23
52-Week
2.08 +47.36%
on 11/08/23
8.20 -62.62%
on 02/24/23
-4.76 (-60.82%)
since 02/23/23

Most Recent Stories

More News
Oncocyte Corporation to Present at the LD Micro Invitational XIII

Irvine, California--(Newsfile Corp. - June 1, 2023) - Oncocyte Corporation (NASDAQ: OCX) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard...

OCX : 3.07 (+0.53%)
Elevance Health (ELV) Tops Q1 Earnings and Revenue Estimates

Elevance Health (ELV) delivered earnings and revenue surprises of 2.16% and 2.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ELV : 514.09 (+0.37%)
OCX : 3.07 (+0.53%)
1 'Buy Now' Stock to Watch, and 2 to Get Rid Of

The Fed’s continued rate hikes and the recent turmoil in the banking system have renewed recession fears lately. Despite growing recessionary pressures, investors shouldn’t shy away from adding fundamentally...

FLGC : 0.9511 (-5.36%)
OCX : 3.07 (+0.53%)
SAIC : 139.26 (+1.01%)
3 Medical Services Stocks to Buy Amid Industry Challenges

The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most. However, staffing shortages may disrupt the trend.

EMBC : 14.84 (+0.61%)
OCX : 3.07 (+0.53%)
INNV : 4.93 (-3.90%)
Life Time Group Holdings, Inc. (LTH) Tops Q4 Earnings and Revenue Estimates

Life Time Group Holdings, Inc. (LTH) delivered earnings and revenue surprises of 16.67% and 0.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

LTH : 12.48 (+2.04%)
OCX : 3.07 (+0.53%)
Viatris (VTRS) Matches Q4 Earnings Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

VTRS : 13.53 (+1.27%)
OCX : 3.07 (+0.53%)
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?

OncoCyte (OCX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OCX : 3.07 (+0.53%)
OncoCyte (OCX) Reports Q3 Loss, Misses Revenue Estimates

OncoCyte (OCX) delivered earnings and revenue surprises of 38.46% and 32.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OCX : 3.07 (+0.53%)
IMCC : 0.3310 (-0.09%)
OncoCyte (OCX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for OncoCyte (OCX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions,...

OCX : 3.07 (+0.53%)
Strength Seen in Cano Health, Inc. (CANO): Can Its 32.2% Jump Turn into More Strength?

Cano Health, Inc. (CANO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

CANO : 2.29 (-0.43%)
OCX : 3.07 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.

See More

Key Turning Points

3rd Resistance Point 3.16
2nd Resistance Point 3.12
1st Resistance Point 3.09
Last Price 3.07
1st Support Level 3.02
2nd Support Level 2.98
3rd Support Level 2.95

See More

52-Week High 8.20
Fibonacci 61.8% 5.86
Fibonacci 50% 5.14
Fibonacci 38.2% 4.42
Last Price 3.07
52-Week Low 2.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar